3 hours ago • PR Newswire
Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study
3 hours ago • PR Newswire
Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study4 hours ago • PR Newswire
Tiger BioSciences Highlights Study on Advanced Placental CAMP Technologies5 hours ago • EIN Presswire
New Peer-Reviewed Study Reveals 'Ghost Rates' Widespread in Federal Price Transparency Data8 hours ago • PR Newswire
Study Reveals AltaMed Health Services Generated $15.1 Billion in Economic Impact While Caring for Hundreds of Thousands of Southern California Patients Demonstrating How Healthy Communities Strengthen Local Economies9 hours ago • tradingview.com
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy10 hours ago • PR Newswire
EyeYon Medical Ltd. Receives FDA IDE Approval to Initiate U.S. Clinical Study of EndoArt®, the First Artificial Endothelial Layer for Corneal Edema11 hours ago • PR Newswire
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder11 hours ago • economictimes.indiatimes.com
Indian employees investing actively but lack financial preparedness and knowledge, study shows12 hours ago • lokmattimes.com
Over 30 minutes of Instagram, Snapchat use may impair children’s attention: Study13 hours ago • oncodaily.com
FDA to Shift Toward Single-Study Requirement for Drug and Medical Product Approvals13 hours ago • globenewswire.com
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 202614 hours ago • PR Newswire
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight15 hours ago • EIN Presswire
Dental Industry Market is expected to accumulate a value of US$ 60.03 Bn by 2035 registering a CAGR of 4.01% -MRFR Study16 hours ago • prnewswire.co.uk
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison17 hours ago • PR Newswire
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder22 hours ago • PR Newswire
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma22 hours ago • PR Newswire
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study2025-12-08 • EIN Presswire
iThemeland Publishes New Study Comparing WooCommerce Bulk Editing Tools Across 2,400 Online Stores2025-12-08 • PR Newswire
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)2025-12-07 • PR Newswire
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition2025-12-06 • finviz.com
BMY Gains on News of Continuation of Alzheimer's Disease Study2025-12-06 • fiercebiotech.com
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune reactions to the investigational treatment recorded in preclinical mouse studies. The regulator has requested that Denali adjust its trial protocol “to include a lower starting dose, revised inclusion criteria, certain safety monitoring commitments and stopping rules,” the Bay Area biotech said in a Dec. 4 filing with the Securities and Exchange Commission (SEC). The FDA identified the concerns during its 30-day review of Denali's Investigational New Drug (IND) application for an enzyme replacement therapy dubbed DNL952. The agency is not asking the biotech to conduct any additional preclinical research. “We have submitted our response to the FDA and plan to start the phase 1 study in the first half of 2026, pending the agency’s feedback,” a Denali spokesperson told Fierce Biotech. Denali doesn't expect the hold to significantly delay its phase 12025-12-06 • medicalxpress.com
Planned birth at term reduces pre-eclampsia in those at high risk, clinical trial finds2025-12-06 • angioedemanews.com
New HAE therapy delivers quicker relief in Phase 3 on-demand study2025-12-06 • tradingview.com
PLATTS: 100--MISO to study 15 more power projects totaling 6.1 GW of capacity in expedited queue2025-12-06 • magazine.cim.org
Vale and Glencore eye joint venture, a prefeasibility study for the Lawyers-Ranch project, and Barrick mulls spinoff of North American assets2025-12-06 • globenewswire.com
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 20252025-12-06 • neurologylive.com
Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease2025-12-06 • medicaldialogues.in
CDSCO Panel Denies Trial Waiver for Atropine, Asks Sun Pharma to Conduct Phase III Study2025-12-06 • thegatewayonline.ca
New clinical trial seeks to uncover the benefits of heavy lifting for cancer survivors48 minutes ago • prnewswire.co.uk
Acute on Chronic Liver Failure Market Set to Grow by 2034 as Novel Therapeutic Approaches Enter Clinical Pipeline | DelveInsight48 minutes ago • newswire.ca
Utilities Trust of Australia acquires Ontario Teachers' majority stake in Sydney Desalination Plant2 hours ago • newswire.ca
Early Warning Report Issued Pursuant to National Instrument 62-103 - Disposition of Securities of Sir Royalty Income Fund.2 hours ago • newswire.ca
GLOBAL X ANNOUNCES SEMI-MONTHLY DECEMBER 2025 DISTRIBUTIONS FOR ITS SUITE OF ETFs3 hours ago • newswire.ca
Media Invitation ─ Talk by Karine Moses, Vice-Chair, Québec and Senior Vice-President, Sales, and Michel Richer, Senior Vice President, Enterprise Solutions, Data Engineering & AI at Bell8 hours ago • retailtechinnovationhub.com
Warehouse and store automation specialist GreyOrange appoints Deepak Sharma as Chief Operating Officer8 hours ago • dailymail.co.uk
Moment Pregnant Girlfriend Proposed Drug Dealing Boyfriend Unaware Police Bust 26million Trafficking Racket.html8 hours ago • wastemanagementreview.com.au
Australia’s reach for global circularity rate and $26 billion boost8 hours ago • hampshire.police.uk
Two Charged In Southampton Murder Investigation8 hours ago • thedefensepost.com
Burkina Faso Releases 8 NGO Members Arrested for ‘Spying’8 hours ago • thedefensepost.com
US OKs Sale of JASSM-ER Missiles to Italy, GBU-39/B Bombs to S. Korea8 hours ago • sentinelassam.com
Assam Approves Transfer of 3,000 Bighas Land for Silchar Greenfield Airport2 minutes ago • EIN Presswire
Adria Nicole Laxson Joins Legacy Makers TV17 minutes ago • EIN Presswire
Get Ready for the 2026 RCA Annual Conference & Culinology® Expo: Innovation at Altitude17 minutes ago • EIN Presswire
Dr. Constance Snead Debuts a Bold Memoir About Leading Fearlessly and Redefining What Leadership Truly Means9 hours ago • defensemirror.com
Russia Lays Out New Transport Aircraft, Large Passenger Jet Plans12 hours ago • tvbrics.com
Omsk launches production of strategic raw materials for aviation and industry8 hours ago • exchange4media.com
Fintech startup Aspora has appointed Varun Sridhar as CEO8 hours ago • sentinelassam.com
Assam Approves Transfer of 3,000 Bighas Land for Silchar Greenfield Airport8 hours ago • india.com
Good news for THIS company as it wins Rs 277-crore NHAI projects in Tamil Nadu, Maharashtra2 hours ago • PR Newswire
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US3 hours ago • EIN Presswire
Miss Grand United Kingdom Announces New National Director, Daniela Costin6 hours ago • EIN Presswire
Buxton’s New Inn Celebrates 1st Birthday with CAMRA ‘Pub of the Season’ AwardStay ahead with real-time headlines from top sources, categorized by sector and country.